Evidence map›Paper›PMID 40834324›Full record

ArticleJCO precision oncology2025

Evaluating the Effect of

Matthew I Ebia, Edik M Blais, Yujie Cui, Emanuel F Petricoin, Michael Pishvaian, Srinivas Gaddam, Jun Gong, Arsen Osipov, Andrew E Hendifar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in JCO precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. KRAS Inhibition in Pancreatic Ductal Adenocarcinoma.Journal of clinical medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Matthew I EbiaCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-7159-1926
Edik M BlaisPerthera, Inc, McLean, VA.ORCID 0000-0001-5609-3849
Yujie CuiCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-8254-6474
Emanuel F PetricoinPerthera, Inc, McLean, VA.ORCID 0000-0001-9146-5572
Michael PishvaianJohns Hopkins University, Baltimore, MD.ORCID 0000-0002-1165-9041
Srinivas GaddamCedars-Sinai Medical Center, Los Angeles, CA.
Jun GongCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-8713-1406
Arsen OsipovCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-9000-7040
Andrew E HendifarCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0002-2079-9177

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTumor molecular profiling is recommended in pancreatic ductal adenocarcinoma (PDAC). However, the predictive and prognostic value of

methodsIn this retrospective analysis using real-world data from patients with early-stage (I to III) and metastatic PDAC who underwent molecular profiling via referrals to Perthera or the PanCAN Know Your Tumor program, patients included were 18 years and older, received standard chemotherapy in the first- and second-line setting, and had complete records. Main outcomes were overall survival (OS) and progression-free survival (PFS) measured from the date of diagnosis of metastatic/recurrent metastatic disease stratified by the

resultsA total of 1359 patients (median [range] age, 64 [28-94] years; 689 [50.7%] male; 707 [52.0%] White) were included.

conclusion

Indexed as

Carcinoma, Pancreatic DuctalPancreatic NeoplasmsProto-Oncogene Proteins p21(ras)AdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTreatment OutcomeKRAS protein, humanProto-Oncogene Proteins p21(ras)

Identifiers

PMID40834324
PMCPMC12379785

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.